Clinical Trial

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Study acronym: EGFR
Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2024 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4 (CDK4) and CDK6 kinase activity. This open-label investigator-initiated trial (IIT) phase I study was designed to evaluate the safety and efficacy of oral BPI-1178 in combination with osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) Mutations.
Protocol Amendment History 1 change
minor Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06362980
Lead Sponsor National Cancer Center, China
Conditions NSCLC
Enrollment 20 participants
Start Date 2024-05-22
Primary Completion 2025-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-10